Neumentum, Inc.

Belkins
Neumentum is developing and plans to commercialize products that have the potential to effectively treat pain, without the risks of abuse, misuse and diversion seen with opioid analgesics. Neumentum’s lead product candidate, NTM-001 (novel, alcohol-free formulation of ketorolac in a pre-mixed bag for continuous IV infusion), has the potential to treat moderately severe acute pain that requires analgesia at the opioid level for up to 24 hours, usually in a postoperative setting, and to reduce the need for opioids.

Related News

PHARMALUTIONS AND MOVILITAS.CLOUD DELIVER SERIALIZATION SOLUTIONS FOR THE ASIA-PACIFIC REGION

Movilitas | September 11, 2020

news image

Movilitas announced Pharmalutions Pte Ltd as its newest Movilitas.Cloud partner for the Asia-Pacific region. Under the partnership, Pharmalutions provides greater access to compliance-ready solutions with Movilitas.Cloud, a GAMP 5 validated software as a service solution (SaaS), and their all-European-made Serialization & Aggregation technologies dedicated to the pharmaceutical industry in the region. Their comprehensive portfolio enables companies to comply with global regulations while imp...

Read More

PHARMACY MARKET

EMA STARTS ROLLING REVIEW OF CUREVAC’S COVID-19 VACCINE (CVNCOV)

CureVac, EMA | February 18, 2021

news image

The European Medicines Agency (EMA's) Committee for Human Medicinal Products (CHMP) has begun a moving audit of CureVac AG's COVID-19 antibodies, CVnCoV. The survey was started on the grounds that starter research facility contemplates and early clinical preliminary outcomes recommend the immunization triggers the creation of antibodies and insusceptible cells that target SARS-CoV-2, the infection that causes COVID‑19. The survey will successively audit info...

Read More

ZEBLOK COMPUTATIONAL ANNOUNCES PARTNERSHIP WITH LAUFER CENTER AND CEWIT - COVID-19 DRUG DISCOVERY

Zeblok Computational, The Laufer Center, CEWIT | July 20, 2020

news image

Zeblok Computational is contributing to the efforts of two groups of researchers at The Laufer Center for Physical and Quantitative Biology, for COVID-19 drug discovery by providing Zeblok’s secure, scalable Supercomputing-as-a-Service platform, employing 128 GPUs from the CEWIT SMART GPU Cluster. The Laufer Center simulations focus on 3 key proteins of the SARS-CoV-2 virus to pinpoint more precisely which drug candidates have the best binding affinity to various protein tar...

Read More

POINT-OF-CARE TOOLS IN PHARMACY TAKE OFF

Managed Healthcare Executive | March 02, 2020

news image

New point-of-care (POC) tools that promote communication between providers and patients are establishing themselves as next generation shared decision-making solutions, especially when it comes to medications and issues of insurance coverage, price, and out-of-pocket costs. “When compared to traditional shared decision-making tools, there’s an increased emphasis not just on improving measures such as medication adherence by involving the patient in his or her own care but also on usi...

Read More

Movilitas | September 11, 2020

news image

PHARMALUTIONS AND MOVILITAS.CLOUD DELIVER SERIALIZATION SOLUTIONS FOR THE ASIA-PACIFIC REGION

Movilitas announced Pharmalutions Pte Ltd as its newest Movilitas.Cloud partner for the Asia-Pacific region. Under the partnership, Pharmalutions provides greater access to compliance-ready solutions with Movilitas.Cloud, a GAMP 5 validated software as a service solution (SaaS), and their all-European-made Serialization & Aggregation technologies dedicated to the pharmaceutical industry in the region. Their comprehensive portfolio enables companies to comply with global regulations while imp...

Read More

PHARMACY MARKET

CureVac, EMA | February 18, 2021

news image

EMA STARTS ROLLING REVIEW OF CUREVAC’S COVID-19 VACCINE (CVNCOV)

The European Medicines Agency (EMA's) Committee for Human Medicinal Products (CHMP) has begun a moving audit of CureVac AG's COVID-19 antibodies, CVnCoV. The survey was started on the grounds that starter research facility contemplates and early clinical preliminary outcomes recommend the immunization triggers the creation of antibodies and insusceptible cells that target SARS-CoV-2, the infection that causes COVID‑19. The survey will successively audit info...

Read More

Zeblok Computational, The Laufer Center, CEWIT | July 20, 2020

news image

ZEBLOK COMPUTATIONAL ANNOUNCES PARTNERSHIP WITH LAUFER CENTER AND CEWIT - COVID-19 DRUG DISCOVERY

Zeblok Computational is contributing to the efforts of two groups of researchers at The Laufer Center for Physical and Quantitative Biology, for COVID-19 drug discovery by providing Zeblok’s secure, scalable Supercomputing-as-a-Service platform, employing 128 GPUs from the CEWIT SMART GPU Cluster. The Laufer Center simulations focus on 3 key proteins of the SARS-CoV-2 virus to pinpoint more precisely which drug candidates have the best binding affinity to various protein tar...

Read More

Managed Healthcare Executive | March 02, 2020

news image

POINT-OF-CARE TOOLS IN PHARMACY TAKE OFF

New point-of-care (POC) tools that promote communication between providers and patients are establishing themselves as next generation shared decision-making solutions, especially when it comes to medications and issues of insurance coverage, price, and out-of-pocket costs. “When compared to traditional shared decision-making tools, there’s an increased emphasis not just on improving measures such as medication adherence by involving the patient in his or her own care but also on usi...

Read More